Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy (NCT03111121) | Clinical Trial Compass
CompletedPhase 4
Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy
United States79 participantsStarted 2017-05-04
Plain-language summary
Use of Muscle relaxant and reversal with Sugammadex at end of airway procedures will reduce the time to extubation after end of procedure
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Microlaryngoscopy or rigid bronchoscopy for vocal cord and tracheal procedures
Age 18 years or older,
ASA physical status I-III
Ability to give written informed consent.
Exclusion Criteria:
Known or suspected neuromuscular disease/pre-existing weakness,
Creatinine clearance less than 30 ml/min
Bradycardia of less than 40 beats/min,
Pregnancy, breast feeding women
Known or suspected allergy to BRIDION® (sugammadex), neostigmine or rocuronium.
Patients with contraindications towards sugammadex, neostigmine or rocuronium
Patients included in another trial within the last 30 days
Patients with legal guardians or surrogate decision making
Patients who refuse to use non-hormonal contraceptive method or back-up method of contraception (such as condoms and spermicides) for the next 7 days if receiving sugammadex.
\-